# Beikang Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beikang-medical

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Latest round: Series A (Nov 10, 2025)
- Investors on record: 2

## About

Founded in 2021 and based in Jiaxing, China, Beikang Medical is a biotechnology company engaged in stem cell culture, differentiation, and industrialization. It is a pioneer in China's in vitro preparation and encapsulation technology of stem cell-derived pancreatic islet cells, possessing fully independent core technologies. In November 2025, Beikang Medical raised a series A funding from new investors Yuanshi Investment and Jiaxing High-tech Zone Industrial Fund Investment Co., Ltd.

The company provides China's in vitro preparation and encapsulation technology of stem cell-derived pancreatic islet cells, dedicated to using stem cell technology to cultivate healthy human tissues or organs to replace diseased tissues.

The company generates revenue by providing China's in vitro preparation and encapsulation technology of stem cell-derived pancreatic islet cells.

The company will use the latest funding to support its core technology research and development and industrialization process, enabling continuous breakthroughs in the field of precision medicine.

## Funding rounds

- Series A, Nov 10, 2025 — Yuanshi Investment, Jiaxing High-tech Zone Industrial Fund Investment Co., Ltd.

## Investors

- Yuanshi Investment (https://capitalatlas.ai/funds/yuanshi-investment) — Series A
- Jiaxing High-tech Zone Industrial Fund Investment Co., Ltd. — Series A